Zevra Therapeutics (ZVRA) Accounts Payables (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Accounts Payables data on file, last reported at $11.7 million in Q1 2026.

• Quarterly Accounts Payables fell 34.41% year-over-year to $11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (down 34.41% YoY) and the FY2025 annual result came in at $11.6 million, down 54.44% from the prior year.
• Accounts Payables grew to $11.7 million in Q1 2026, from $11.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $28.4 million in Q4 2023 to a low of $393000.0 in Q1 2023.
• A 5-year average of $14.0 million and a median of $12.4 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables sank 84.78% — and 2024, when it soared 5697.71%.
• Tracing ZVRA's Accounts Payables over 5 years: stood at $3.6 million in 2022, then surged by 686.57% to $28.4 million in 2023, then decreased by 10.38% to $25.5 million in 2024, then slumped by 54.44% to $11.6 million in 2025, then climbed by 0.78% to $11.7 million in 2026.
• The last three Accounts Payables figures came in at $11.7 million (Q1 2026), $11.6 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.